| BASEC ID | Project title | Type of project | Type of clinical trial | Study phase (clinical trials only) | multi- / monocentric | Category | Principal investigator | Sponsor | Investigational sites | Lead EC | Local EC(s) | Approval date | Minors | Study Ended | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-00215 | CAIN457E22101 - An open-label, multicenter study to evaluate the pharmacokinetics, safety and tolerability of intravenous secukinumab infusion in adults with giant cell arteritis (GCA) or polymyalgia More ... | clinical trial | drugs | phase 1 | multicentric | C | Prof. Dr. med. Thomas Daikeler | Novartis Pharma Schweiz AG |
Universitätsspital Basel, Basel Inselspital Bern - Universitätsspital, Bern Kantonsspital St. Gallen, St. Gallen |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Bern | 04.04.2024 | |||
| 2023-02334 | Anticoagulation for Stroke Prevention in Patients with Recent Episodes of Perioperative Atrial Fibrillation after Non-Cardiac Surgery | clinical trial | drugs | phase 4 | monocentric | A | Dr. med. Philipp Krisai | Population Health Research Institute |
University Hospital Basel, Basel |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 13.02.2024 | ||||
| 2023-02317 | Optimizing Dosing Strategies in Oral Iron Supplementation | clinical trial | drugs | phase 4 | monocentric | A | Prof. Dr. med. Balthasar Hug | Luzerner Kantonsspital |
Luzerner Kantonsspital, Luzern |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 26.01.2024 | ||||
| 2023-02198 | A randomized phase 2 proof-of-concept study to evaluate the efficacy and safety of topical bimiralisib application in patients suffering from actinic keratosis on the face and/or scalp and/or back of More ... | clinical trial | drugs | phase 2 | multicentric | C | Prof. Dr. Alexander Navarini | TORQUR AG |
University Hospital Basel, Basel CHUV centre hospitalier universitaire vaudois, Head of the Onco-dermatology/ Surgery/ Laser Unit, Department of Dermatology and Venereology, Hôpital de Beaumont, Offi More ... |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Commission cantonale d'Éthique de la Recherche sur l'être humain Vaud (CER-VD) | 28.02.2024 | |||
| 2023-02099 | TROPION Breast04 - A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadj More ... | clinical trial | drugs | phase 3 | multicentric | C | Prof. Dr. med. Christian Kurzeder | AstraZeneca AG |
Universitätsspital Basel, Brustzentrum, Basel Inselspital, Universitätsspital Bern, Bern Kantonsspital Baden AG, Department Frauen und Kinder, 5404 Baden Spital Thurgau AG, Frauenfeld Hopital Riviera- More ... |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Ethikkommission Nordwest- und Zentralschweiz EKNZ, Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Bern, Commission cantonale d'Éthique de la Recherche sur l'être humain Vaud (CER-VD) | 18.01.2024 | |||
| 2023-01981 |
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors: The COPPER PET in NET Study A prospective, open-label, randomized, controlled, single centre, phase I/II PET/CT study |
clinical trial | drugs | phase 1/2 | monocentric | C | Dr. Guillaume Nicolas | Universitätsspital Basel |
University Hospital Basel, Basel |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 13.03.2024 | ||||
| 2023-01868 | Targeted radionuclide therapy in metastatic prostate cancer using a new PSMA ligand radiolabelled with terbium-161 (161Tb-SibuDab) - dose identification/escalation phase Ia/b study | clinical trial | drugs | phase 1 | monocentric | C | Dr. Alin Chirindel | USB |
University Hospital Basel, Basel |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 06.11.2023 | ||||
| 2023-01795 | PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study) | clinical trial | drugs | phase 3 | monocentric | C | Dr. Maximilian Pfau | Belite Bio Inc. |
Universitätsspital Basel, Basel |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 19.04.2024 | ||||
| 2023-01643 |
A Phase 3b, multi-center, randomized, parallel group, open-label, non-inferiority study evaluating the efficacy, safety, and tolerability of oral dolutegravir/lamivudine once-daily as a first-line More ... |
clinical trial | drugs | phase 3 | multicentric | A | Dr.med. / Marcel / Stöckle | ViiV Healthcare UK Limited |
Universitätsspital Basel, Basel CHECKPOINT Zürich, Zürich |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Kantonale Ethikkommission Zürich | 03.01.2024 | |||
| 2023-01627 |
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum |
clinical trial | drugs | phase 3 | monocentric | C | Prof. Dr. med. Dr. sc. nat Alexander Navarini | InflaRx GmbH |
Universitätsspital Basel, Klinik für Dermatologie, 4031 Basel |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 07.11.2023 | ||||
| 2023-01540 |
NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED S More ... |
clinical trial | drugs | phase 2 | monocentric | A | Prof. Oliver Riesterer | Kantonsspital Aarau |
Kantonsspital, Aarau |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 13.10.2023 | ||||
| 2023-01489 | CAAA617D12302: An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or d More ... | clinical trial | drugs | phase 3 | multicentric | B | PD Dr. med. Janusch Blautzik | Novartis Pharma Schweiz AG |
Hirslanden Klinik St. Anna, Luzern Hôpitaux universitaire de Genève, Geneva Stadtspital Zürich,, Zürich |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Kantonale Ethikkommission Zürich, Commission Cantonale d'éthique de la recherche Genève (CCER) | 22.11.2023 | |||
| 2023-01469 | Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor TKI)-naïve ROS1-positive Non-Small C More ... | clinical trial | drugs | phase 3 | monocentric | C | Prof. Dr. Dr. Sacha Rothschild | Bristol-Myers Squibb Services Unlimited Company |
Kantonsspital Baden AG, Baden |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 07.12.2023 | ||||
| 2023-01421 | PREcooPera:A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer | clinical trial | drugs | phase 2 | multicentric | C | Prof. Dr. med. Peter Dubsky | ETOP IBCSG Partner foundation |
Hirslanden Klinik St. Anna, Luzern Kantonsspital Baden, Department of Gynecology, Baden Brustzentrum Basel Bethesda Spital, Basel Spital Thurgau, Frauenfeld Instituto Oncologico della Swizzera Italian More ... |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Ethikkommission Nordwest- und Zentralschweiz EKNZ, Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Zürich, Commission cantonale d'Éthique de la Recherche sur l'être humain Vaud (CER-VD), More ... | 09.10.2023 | |||
| 2023-01387 |
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with Type 2 Diabetes Mellitus (Dapan-Dia-Study) Prot More ... |
clinical trial | drugs | phase 2 | monocentric | C | Prof. Marc Donath | University Hospital Basel |
University Hospital Basel, Basel |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 24.01.2024 | ||||
| 2023-01281 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis | clinical trial | drugs | phase 3 | multicentric | C | Katrin Esther Hostettler Haack | Bristol-Myers Squibb Services Unlimited Company |
Universitätsklinikum Basel, Basel Universitaetsspital Bern, Bern |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Kantonale Ethikkommission Bern | 31.08.2023 | |||
| 2023-01265 | BO44426 - A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF DIVARASIB IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UN More ... | clinical trial | drugs | phase 1/2 | multicentric | C | Dr. med. David König | Roche Pharma (Schweiz) AG |
Universitätsspital Basel, Basel Insel Gruppe AG, Inselspital Bern, Bern |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Kantonale Ethikkommission Bern | 21.09.2023 | |||
| 2023-01104 | 20190341- A Phase 3 multicenter, randomized, open label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in More ... | clinical trial | drugs | phase 3 | multicentric | C | Prof Dr Med Sacha Rothschild | Amgen Switzerland AG |
Kantonsspital Baden, Baden Medizinische Universitätsklinik Kantonsspital Aarau, Aarau Universitaetsspital Basel, Basel Universitätsspital Zürich, Zuerich |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Ethikkommission Nordwest- und Zentralschweiz EKNZ, Kantonale Ethikkommission Zürich | 03.10.2023 | |||
| 2023-01102 | A Phase 3, Open-label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti‑CD20 x Anti-CD3 Bispecific Antibody, Versus Investigator’s Choice in Previously Untreated More ... | clinical trial | drugs | phase 3 | multicentric | C | Dr. Fatime Kransiqi | Regeneron Pharmaceuticals, Inc. |
University Hospital Basel, Medical Oncology, Petersgraben 4, Basel Inselspital / Bern University Hospital, Medizinische Onkologie, Freiburgstrasse 41, Bern Kantonsspital Baden, Im Ergel 1, 5404 Baden, More ... |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | Ethikkommission Nordwest- und Zentralschweiz EKNZ, Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Bern, Kantonale Ethikkommission Zürich | 29.11.2023 | |||
| 2023-01010 |
Oxytocin substitution therapy in patients with central diabetes insipidus: a double-blind randomized placebo-controlled trial |
clinical trial | drugs | phase 2 | monocentric | B | Prof Mirjam Christ-Crain | Universitätsspital Basel |
University Hospital Basel, Basel |
Ethikkommission Nordwest- und Zentralschweiz EKNZ | 27.07.2023 | ||||